InMed Pharmaceuticals (INM) Other financing activities (2020 - 2025)
InMed Pharmaceuticals (INM) posted quarterly Other financing activities of $3.8 million for Q2 2025, up 376907800.0% year-over-year from N/an in Q2 2024, and up 28.42% quarter-over-quarter from $2.9 million in Q1 2025.
InMed Pharmaceuticals (INM) Other financing activities (2020 - 2025) Analysis & Trends
InMed Pharmaceuticals' Other financing activities history runs 6 years deep, the most recent figure standing at $3.8 million for Q2 2025.
- In Q2 2025, Other financing activities rose 376907800.0% year-over-year to $3.8 million; the TTM figure through Jun 2025 stood at $8.1 million (up 12736.07% YoY), while the FY2025 annual figure was $8.1 million, up 55.87% from the prior year.
- Other financing activities for Q2 2025 stood at $3.8 million, up from $2.9 million in the prior quarter.
- The five-year high for Other financing activities was $10.2 million in Q4 2022, with the low at -$63697.0 in Q1 2023.
- The 5-year median for Other financing activities is $454089.5 (2021), against an average of $1.5 million.
- The sharpest annual moves came in 2023 and 2025: Other financing activities sank 100.13% in 2023, then jumped 376907800.0% in 2025.
- InMed Pharmaceuticals' Other financing activities stood at $179118.0 in 2021, then surged by 5579.55% to $10.2 million in 2022, then sank by 100.01% to -$646.0 in 2023, then soared by 61423.99% to $396153.0 in 2024, then soared by 851.42% to $3.8 million in 2025.
- Business Quant data shows INM's Other financing activities at $3.8 million in Q2 2025, $2.9 million in Q1 2025, and $396153.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 3.77 Mn |
| Jun 30, 2025 | 3.77 Mn |
| Mar 31, 2025 | 2.94 Mn |
| Mar 31, 2025 | 2.94 Mn |
| Dec 31, 2024 | 396,153.00 |
| Dec 31, 2024 | 396,153.00 |
| Sep 30, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.00 |
| Jun 30, 2024 | 1.00 |
| Jun 30, 2023 | -646.00 |
| Jun 30, 2023 | -646.00 |
| Mar 31, 2023 | -63,697.00 |
| Mar 31, 2023 | -63,697.00 |
| Dec 31, 2022 | 10.17 Mn |
| Dec 31, 2022 | 10.17 Mn |
| Sep 30, 2022 | 571,261.00 |
| Sep 30, 2022 | 571,261.00 |
| Jun 30, 2022 | 490,544.00 |
| Jun 30, 2022 | 490,544.00 |